Company
Every investor coverage indicates participated in a round US COPD Foundation raised.
Companies US COPD Foundation acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming US COPD Foundation. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne-based ENA Respiratory announced US patent allowances covering its TLR2 agonist platform and a COPD treatment method, strengthening IP protection for its INNA-051 nasal spray candidate now in Phase II testing.
Melbourne biotech ENA Respiratory has begun dosing volunteers in a mid-stage trial of its INNA-051 antiviral spray, aimed at limiting common viral illnesses in at-risk groups.
Melbourne pharmaceutical company ENA Respiratory has received US$5 million from California's Flu Lab to advance clinical testing of its nasal immune-boosting antiviral candidate INNA-051.
Melbourne's ENA Respiratory has won a further US$3.18 million US Defense Department contract to widen its INNA-051 Phase Ib trial to younger adults, extending the US$8.18 million the agency had already committed.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·enarespiratory.com